208 related articles for article (PubMed ID: 19183107)
1. Transferrin receptor-targeted lipid nanoparticles for delivery of an antisense oligodeoxyribonucleotide against Bcl-2.
Yang X; Koh CG; Liu S; Pan X; Santhanam R; Yu B; Peng Y; Pang J; Golan S; Talmon Y; Jin Y; Muthusamy N; Byrd JC; Chan KK; Lee LJ; Marcucci G; Lee RJ
Mol Pharm; 2009; 6(1):221-30. PubMed ID: 19183107
[TBL] [Abstract][Full Text] [Related]
2. Efficient delivery of a Bcl-2-specific antisense oligodeoxyribonucleotide (G3139) via transferrin receptor-targeted liposomes.
Chiu SJ; Liu S; Perrotti D; Marcucci G; Lee RJ
J Control Release; 2006 May; 112(2):199-207. PubMed ID: 16564596
[TBL] [Abstract][Full Text] [Related]
3. Transferrin receptor targeted lipopolyplexes for delivery of antisense oligonucleotide g3139 in a murine k562 xenograft model.
Zhang X; Koh CG; Yu B; Liu S; Piao L; Marcucci G; Lee RJ; Lee LJ
Pharm Res; 2009 Jun; 26(6):1516-24. PubMed ID: 19291371
[TBL] [Abstract][Full Text] [Related]
4. Delivery of antisense oligodeoxyribonucleotide lipopolyplex nanoparticles assembled by microfluidic hydrodynamic focusing.
Koh CG; Zhang X; Liu S; Golan S; Yu B; Yang X; Guan J; Jin Y; Talmon Y; Muthusamy N; Chan KK; Byrd JC; Lee RJ; Marcucci G; Lee LJ
J Control Release; 2010 Jan; 141(1):62-9. PubMed ID: 19716852
[TBL] [Abstract][Full Text] [Related]
5. Targeted delivery of antisense oligodeoxynucleotide by transferrin conjugated pH-sensitive lipopolyplex nanoparticles: a novel oligonucleotide-based therapeutic strategy in acute myeloid leukemia.
Jin Y; Liu S; Yu B; Golan S; Koh CG; Yang J; Huynh L; Yang X; Pang J; Muthusamy N; Chan KK; Byrd JC; Talmon Y; Lee LJ; Lee RJ; Marcucci G
Mol Pharm; 2010 Feb; 7(1):196-206. PubMed ID: 19852511
[TBL] [Abstract][Full Text] [Related]
6. A Polyethylenimine-Containing and Transferrin-Conjugated Lipid Nanoparticle System for Antisense Oligonucleotide Delivery to AML.
Yuan Y; Zhang L; Cao H; Yang Y; Zheng Y; Yang XJ
Biomed Res Int; 2016; 2016():1287128. PubMed ID: 27034925
[TBL] [Abstract][Full Text] [Related]
7. Lipid Nanoparticles Loaded with an Antisense Oligonucleotide Gapmer Against Bcl-2 for Treatment of Lung Cancer.
Cheng X; Liu Q; Li H; Kang C; Liu Y; Guo T; Shang K; Yan C; Cheng G; Lee RJ
Pharm Res; 2017 Feb; 34(2):310-320. PubMed ID: 27896589
[TBL] [Abstract][Full Text] [Related]
8. Coaxial electrohydrodynamic spraying: a novel one-step technique to prepare oligodeoxynucleotide encapsulated lipoplex nanoparticles.
Wu Y; Yu B; Jackson A; Zha W; Lee LJ; Wyslouzil BE
Mol Pharm; 2009; 6(5):1371-9. PubMed ID: 19499922
[TBL] [Abstract][Full Text] [Related]
9. Efficient delivery of an antisense oligodeoxyribonucleotide formulated in folate receptor-targeted liposomes.
Chiu SJ; Marcucci G; Lee RJ
Anticancer Res; 2006; 26(2A):1049-56. PubMed ID: 16619505
[TBL] [Abstract][Full Text] [Related]
10. Efficient delivery of the Bcl-2 antisense oligonucleotide G3139 via nucleus-targeted aCD33-NKSN nanoparticles.
Yan C; Gu J; Zhang Y; Ma K; Lee RJ
Int J Pharm; 2022 Sep; 625():122074. PubMed ID: 35932928
[TBL] [Abstract][Full Text] [Related]
11. Phosphorothioate oligodeoxynucleotides and G3139 induce apoptosis in 518A2 melanoma cells.
Lai JC; Benimetskaya L; Khvorova A; Wu S; Hua E; Miller P; Stein CA
Mol Cancer Ther; 2005 Feb; 4(2):305-15. PubMed ID: 15713901
[TBL] [Abstract][Full Text] [Related]
12. T7 Peptide-Conjugated Lipid Nanoparticles for Dual Modulation of Bcl-2 and Akt-1 in Lung and Cervical Carcinomas.
Cheng X; Yu D; Cheng G; Yung BC; Liu Y; Li H; Kang C; Fang X; Tian S; Zhou X; Liu Q; Lee RJ
Mol Pharm; 2018 Oct; 15(10):4722-4732. PubMed ID: 30138565
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of potentially anti-apoptotic proteins by antisense protein kinase C-alpha (Isis 3521) and antisense bcl-2 (G3139) phosphorothioate oligodeoxynucleotides: relationship to the decreased viability of T24 bladder and PC3 prostate cancer cells.
Benimetskaya L; Miller P; Benimetsky S; Maciaszek A; Guga P; Beaucage SL; Wilk A; Grajkowski A; Halperin AL; Stein CA
Mol Pharmacol; 2001 Dec; 60(6):1296-307. PubMed ID: 11723237
[TBL] [Abstract][Full Text] [Related]
14. BCL-2 antisense oligonucleotide genasense is active against imatinib-resistant BCR-ABL-positive cells.
Tauchi T; Sumi M; Nakajima A; Sashida G; Shimamoto T; Ohyashiki K
Clin Cancer Res; 2003 Sep; 9(11):4267-73. PubMed ID: 14519654
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activity of G3139 lipid nanoparticles (LNPs).
Pan X; Chen L; Liu S; Yang X; Gao JX; Lee RJ
Mol Pharm; 2009; 6(1):211-20. PubMed ID: 19072654
[TBL] [Abstract][Full Text] [Related]
16. Disulfide-linked liposomes: effective delivery vehicle for Bcl-2 antisense oligodeoxyribonucleotide G3139.
Weecharangsan W; Yu B; Liu S; Pang JX; Lee LJ; Marcucci G; Lee RJ
Anticancer Res; 2010 Jan; 30(1):31-7. PubMed ID: 20150614
[TBL] [Abstract][Full Text] [Related]
17. Electroporation increases antitumoral efficacy of the bcl-2 antisense G3139 and chemotherapy in a human melanoma xenograft.
Spugnini EP; Biroccio A; De Mori R; Scarsella M; D'Angelo C; Baldi A; Leonetti C
J Transl Med; 2011 Jul; 9():125. PubMed ID: 21798045
[TBL] [Abstract][Full Text] [Related]
18. G3139 induces cell death by caspase-dependent and -independent apoptosis on human melanoma cell lines.
Nakamura S; Inui M; Kamei T; Nakase M; Okumura K; Tagawa T
Oncol Rep; 2006 Jun; 15(6):1563-8. PubMed ID: 16685396
[TBL] [Abstract][Full Text] [Related]
19. Effects of Bcl-2 modulation with G3139 antisense oligonucleotide on human breast cancer cells are independent of inherent Bcl-2 protein expression.
Chi KC; Wallis AE; Lee CH; De Menezes DL; Sartor J; Dragowska WH; Mayer LD
Breast Cancer Res Treat; 2000 Oct; 63(3):199-212. PubMed ID: 11110054
[TBL] [Abstract][Full Text] [Related]
20. Targeted delivery of antisense oligodeoxynucleotide and small interference RNA into lung cancer cells.
Li SD; Huang L
Mol Pharm; 2006; 3(5):579-88. PubMed ID: 17009857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
